



## Nurturing early-stage companies to accelerate transformative innovation

Our multifaceted initiative in Europe, Johnson & Johnson Innovation, JLINX (JLINX) has been uniquely designed to identify and nurture early-stage companies actively pursuing research with the potential to transform human health. By offering start-ups a spectrum of flexible ways to grow and collaborate across the European life science ecosystem, we aim to catalyze scientific advances and accelerate breakthroughs.

The day-to-day operations are managed through a close collaboration with Biocube Ventures, an experienced life science incubation and investor management team, which will provide independent oversight for venture funding and company selection.

JLINX complements and extends the Johnson & Johnson Innovation network of initiatives to create a unique environment to advance your scientific research and development for the benefit of patients. JLINX is venture-based and Johnson & Johnson companies will not hold any specific rights to commercialized products by virtue of the JLINX relationship.

“Our mission is to identify and advance the best science – internal or external – to bring healthcare solutions to patients and consumers around the world.”

– Paul Stoffels, M.D.,

Chief Scientific Officer and  
Worldwide Chairman, Pharmaceuticals,  
Johnson & Johnson

## Our unique approach to support you

At JLINX we can provide opportunities to share ideas and collaborate with other entrepreneurs while accessing a unique combination of resources including investment, infrastructure and relevant internal and external scientific, technical and business expertise.

Located in a fully dedicated facility on the Janssen Campus in Beerse, Belgium, JLINX:

- is designed to foster a creative start-up culture
- provides access to the best scientific talent and resources on the Janssen Campus
- draws upon the full global scientific resources of Johnson & Johnson Innovation
- is focused on human microbiome research, alongside other areas of innovation in pharmaceuticals and cross-disciplinary healthcare solutions



Interested in applying to join the JLINX community? Visit [jlinx.jnjinnovation.com](http://jlinx.jnjinnovation.com)

## Contacts

### **Kurt Hertogs, PhD**

Head of JLINX

Johnson & Johnson Innovation

[khertog1@its.jnj.com](mailto:khertog1@its.jnj.com)

### **Nico Vandervelpen, MSc**

Managing Director and Cofounder

Bioqube Ventures

[nico@bioqubeventures.com](mailto:nico@bioqubeventures.com)

### **Tom Aelbrecht, MSc**

Head of the Janssen Campus Office (JCO)

[taelbrec@its.jnj.com](mailto:taelbrec@its.jnj.com)

### **Debora Dumont, PhD**

Managing Director and Cofounder

Bioqube Ventures

[debbie@bioqubeventures.com](mailto:debbie@bioqubeventures.com)